Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice

膜结合的mRNA免疫原降低了人源化小鼠体内激活HIV Env V2顶端导向的广谱中和B细胞前体的阈值。

阅读:4
作者:Eleonora Melzi ,Jordan R Willis ,Krystal M Ma ,Ying-Cing Lin ,Sven Kratochvil ,Zachary T Berndsen ,Elise A Landais ,Oleksandr Kalyuzhniy ,Usha Nair ,John Warner ,Jon M Steichen ,Anton Kalyuzhniy ,Amber Le ,Simone Pecetta ,Manfredo Perez ,Kathrin Kirsch ,Stephanie R Weldon ,Samantha Falcone ,Sunny Himansu ,Andrea Carfi ,Devin Sok ,Andrew B Ward ,William R Schief ,Facundo D Batista

Abstract

Eliciting broadly neutralizing antibodies (bnAbs) is the core of HIV vaccine design. bnAbs specific to the V2-apex region of the HIV envelope acquire breadth and potency with modest somatic hypermutation, making them attractive vaccination targets. To evaluate Apex germline-targeting (ApexGT) vaccine candidates, we engineered knockin (KI) mouse models expressing the germline B cell receptor (BCR) of the bnAb PCT64. We found that high affinity of the ApexGT immunogen for PCT64-germline BCRs was necessary to specifically activate KI B cells at human physiological frequencies, recruit them to germinal centers, and select for mature bnAb mutations. Relative to protein, mRNA-encoded membrane-bound ApexGT immunization significantly increased activation and recruitment of PCT64 precursors to germinal centers and lowered their affinity threshold. We have thus developed additional models for HIV vaccine research, validated ApexGT immunogens for priming V2-apex bnAb precursors, and identified mRNA-LNP as a suitable approach to substantially improve the B cell response.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。